The recent disruptions in global chains have highlighted the value of securing essential medications like Ivermectin. Trusting on overseas manufacturers exposes countries to considerable vulnerabilities, including delivery delays, price fluctuations, and even trade risks. Transitioning towards domestic production of Ivermectin offers a multitude of